Department of Molecular Oncology & Precision Medicine Department of Molecular Oncology & Precision Medicine
Request an appointment Consult our Cancer Specialists
NABL Accreditation

NABL Accredited Laboratory

Our Molecular Diagnostics Department is NABL accredited, ensuring the highest standards of quality and precision in diagnostic services.

Vision & Mission

The Department of Molecular Oncology & Precision Medicine at SSCHRC represents a paradigm shift in cancer care—integrating cutting-edge molecular diagnostics and translational research to deliver truly personalized cancer treatment. As a quaternary care referral center, we are committed to advancing precision oncology through comprehensive molecular profiling, biomarker-driven therapeutic strategies, and translational research that bridges bench to bedside.

Our mission is threefold: to provide state-of-the-art molecular diagnostic services that guide clinical decision-making, to establish a world-class translational research program anchored by a comprehensive biorepository, and to generate knowledge that transforms our understanding of cancer biology and therapeutic resistance.

Molecular Diagnostics & Precision Medicine Platform

Our NABL-accredited molecular diagnostics laboratory offers comprehensive molecular profiling services across multiple technology platforms, serving as the cornerstone of precision oncology at SSCHRC.

Genomic Profiling Services

Next-Generation Sequencing (NGS)

Comprehensive tumor profiling including targeted gene panels, whole exome sequencing, and transcriptome analysis for actionable mutations and therapeutic biomarkers.

Liquid Biopsy

Circulating tumor DNA (ctDNA) analysis for minimal residual disease monitoring, treatment response assessment, and resistance mutation detection.

Germline Testing

Hereditary cancer syndrome panels covering BRCA1/2, Lynch syndrome, and over 80 cancer predisposition genes.

Pharmacogenomics

Germline variants affecting drug metabolism to optimize therapeutic dosing and minimize toxicity.

PCR based Mutation testing

PCR based Mutation testing for multiple genes like EGFR, RAS family and POL- E.

Advanced Molecular Pathology

Flow Cytometry

Multi-parameter immunophenotyping for hematological malignancies with comprehensive aberrancy detection.

Cytogenetics & FISH

Chromosomal aberration analysis and fusion gene detection across solid and liquid tumors.

Emerging Technologies

Mass Spectrometry-Based Proteomics

Protein biomarker discovery, metabolomic profiling, and tissue imaging mass spectrometry for spatial molecular characterization.

Single-Cell Genomics

Tumor heterogeneity analysis and clonal evolution studies.

Translational Research Program

Our translational research initiative is designed to accelerate the translation of laboratory discoveries into clinical applications, with a focus on understanding the molecular mechanisms driving cancer initiation, progression, therapeutic resistance, and metastasis.

Research Themes

Tumor Microenvironment & Immunotherapy

  • Immune checkpoint regulation and mechanisms of immunotherapy resistance
  • Tumor-infiltrating lymphocyte profiling and predictive biomarker development
  • Cancer-associated fibroblasts and extracellular matrix remodeling in metastatic dissemination

Cancer Metabolism & Therapeutic Vulnerabilities

  • Metabolic reprogramming in cancer cells and the tumor microenvironment
  • Targeting metabolic dependencies for novel therapeutic strategies
  • Mitochondrial dysfunction and oxidative stress in drug resistance

Precision Oncology & Biomarker Discovery

  • Multi-omics integration for patient stratification and treatment selection
  • Circulating biomarkers for early detection and therapeutic monitoring
  • Mechanisms of acquired resistance to targeted therapies

Metastasis & Tumor Evolution

  • Dissemination of tumor cells and dormancy mechanisms
  • Clonal evolution and intratumor heterogeneity
  • Epithelial-mesenchymal transition and stemness plasticity

Epigenetics & Gene Regulation

  • Chromatin remodeling and transcriptional regulation in cancer
  • DNA methylation and histone modification patterns as therapeutic targets
  • Non-coding RNA networks in cancer progression

World-Class Biorepository & Bioinformatics Infrastructure

The SSCHRC Biobank

Our comprehensive biorepository is the foundation of our translational research program, designed to international standards and operated under stringent ethical and regulatory frameworks:

Prospectively Collected Specimens

Matched tumor tissue, adjacent normal tissue, blood (plasma, serum, buffy coat), and serial biopsies with comprehensive clinical annotation.

Standardized Protocols

Tissue processing within 30 minutes of surgical excision, cryopreservation at -80°C and liquid nitrogen storage, quality-controlled nucleic acid extraction.

Rich Clinical Data Integration

Longitudinal clinical data including treatment history, response assessments, imaging, and patient outcomes linked to biospecimens.

Computational Biology & Bioinformatics Core

High-Performance Computing

High-performance computing infrastructure for multi-omics data analysis.

Custom Bioinformatics Pipelines

Custom bioinformatics pipelines for variant calling, pathway analysis, and biomarker discovery.

Machine Learning & AI

Machine learning and AI-driven predictive modeling for clinical outcomes.

Consortium Integration

Integration with national and international cancer genomics consortia.

National & International Collaborative Networks

SSCHRC is embedded within a global ecosystem of cancer research excellence:

Indian Cancer Genome Atlas (ICGA)

Leading contributor generating comprehensive multi-omics data from diverse Indian cancer cohorts to establish ancestry-specific genomic landscapes.

Academic Partnerships

Active collaborations with Indian Institute of Science, St. John's Research Institute, National Institute of Biomedical Genomics (Kolkata), and Institute of Genomics and Integrative Biology (New Delhi).

International Collaborations

Research partnerships with Institute of Cancer Research (UK), University of Nottingham, Mayo Clinic, USA and other leading global cancer centers.

Industry Partnerships

Collaborative research and clinical trial participation with pharmaceutical and biotechnology companies.

Training & Education

The department serves as a training hub for the next generation of cancer researchers and precision medicine specialists:

PhD Program

Integrated doctoral training in molecular cancer biology and translational research.

Clinical Fellowship

Molecular pathology and precision oncology training for clinicians.

Continuing Medical Education

Regular workshops, seminars, and symposia on advances in molecular diagnostics and precision medicine.

Intern Training Programs

Intensive on ground training internships for Life Science grads and Bioinformatics students.

Impact & Future Directions

The Department of Molecular Oncology & Precision Medicine is committed to:

Advancing Precision Medicine

Making advanced molecular diagnostics accessible across socioeconomic strata.

Biomarker-Driven Clinical Trials

Developing novel therapeutic strategies based on molecular insights from our biobank.

Artificial Intelligence Integration

Leveraging AI for pattern recognition in multi-omics data and clinical decision support.

Liquid Biopsy Program

Expanding non-invasive monitoring capabilities for early detection and treatment response.

Functional Precision Medicine

Moving beyond genomic profiling to incorporate functional testing of patient-derived models.

Contact & Collaboration

We welcome collaborative research opportunities, clinical trial partnerships, and translational research initiatives aligned with our mission to transform cancer care through precision medicine.

Department of Molecular Oncology & Precision Medicine
Sri Shankara Cancer Hospital and Research Center
Advancing Precision Oncology Through Innovation & Collaboration

Our Molecular Oncology Specialists

Meet our specialized molecular oncology experts dedicated to precision cancer diagnostics and research.